Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.


Journal Article

BACKGROUND: The plasma-derived, highly purified, nanofiltered C1-inhibitor concentrate (Berinert; "pnfC1-INH") is approved in the United States for treating hereditary angioedema (HAE) attacks and in many European countries for attack treatment and short-term prophylaxis. OBJECTIVE: The objective of this study was to describe safety and usage patterns of pnfC1-INH. METHODS: A multicenter, observational, registry was conducted between 2010 and 2014 at 30 United States and 7 European sites to obtain both prospective (occurring after enrollment) and retrospective (occurring before enrollment) safety and usage data on subjects receiving pnfC1-INH for any reason. RESULTS: Of 343 enrolled patients, 318 received 1 or more doses of pnfC1-INH for HAE attacks (11,848 infusions) or for prophylaxis (3142 infusions), comprising the safety population. Median dosages per infusion were 10.8 IU/kg (attack treatment) and 16.6 IU/kg (prophylaxis). Approximately 95% of infusions were administered outside of a health care setting. No adverse events (AEs) were reported in retrospective data. Among prospective data (n = 296 subjects; 9148 infusions), 252 AEs were reported in 85 (28.7%) subjects (rate of 0.03 events/infusion); 9 events were considered related to pnfC1-INH. Two thromboembolic events were reported in subjects with thrombotic risk factors. No patient was noted to have undergone viral testing for suspected blood-borne infection during registry participation. CONCLUSIONS: The findings from this large, international patient registry documented widespread implementation of pnfC1-INH self-administration outside of a health care setting consistent with current HAE guidelines. These real-world data revealed pnfC1-INH usage for a variety of reasons in patients with HAE and showed a high level of safety regardless of administration setting or reason for use.

Full Text

Cited Authors

  • Riedl, MA; Bygum, A; Lumry, W; Magerl, M; Bernstein, JA; Busse, P; Craig, T; Frank, MM; Edelman, J; Williams-Herman, D; Feuersenger, H; Rojavin, M; Berinert Registry investigators,

Published Date

  • September 2016

Published In

Volume / Issue

  • 4 / 5

Start / End Page

  • 963 - 971

PubMed ID

  • 27286778

Pubmed Central ID

  • 27286778

Electronic International Standard Serial Number (EISSN)

  • 2213-2201

Digital Object Identifier (DOI)

  • 10.1016/j.jaip.2016.04.018


  • eng

Conference Location

  • United States